🇺🇸 FDA
Pipeline program

laquinimod 0.3

LAQ/5062

Phase 2 small_molecule completed

Quick answer

laquinimod 0.3 for Relapsing Remitting Multiple Sclerosis is a Phase 2 program (small_molecule) at TEVA PHARMACEUTICAL INDUSTRIES LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TEVA PHARMACEUTICAL INDUSTRIES LTD
Indication
Relapsing Remitting Multiple Sclerosis
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials